NCT06220396 CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study
| NCT ID | NCT06220396 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-01-22 |
| Primary Completion | 2029-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-01-22 with a primary completion date of 2029-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate pulmonary capillary wedge pressure (PCWP) and other hemodynamic measurements at rest and during exercise in healthy volunteers across the age spectrum.
Eligibility Criteria
Inclusion Criteria: * Apparently healthy volunteers are eligible to participate in this study if they are free of symptoms of exertional breathlessness or fatigue and any diagnosis of heart failure. * Patients will also be required to have left ventricular ejection fraction (EF) ≥ 50%. * Patients discovered to reduced EF or abnormal resting hemodynamics or other pathologic findings previously undiscovered will be considered screen failures and can be replaced by others to reach the goal enrollment. * Informed consent were obtained. * No history of heart failure. * Willing and able to undergo invasive hemodynamic exercise testing, MRI, and other study assessments. Exclusion Criteria: * Clinically significant symptoms of exertional dyspnea or fatigue in daily life in the opinion of the investigators. * Any diagnosis of heart failure * Symptomatic coronary artery disease (e.g., patients with chronic angina) * Symptomatic valvular heart disease * Pulmonary hypertension * Cardiomyopathies * High output heart failure * Pericardial disease * Clinically significant chronic lung disease in the opinion of the investigators * Anemia (hemoglobin \<12 gm/dL in women and \<13 gm/dL in men) * Estimated glomerular filtration rate ≤30mL/min * Pregnant women * Any other disorders or problems that would interfere with the ability to participate safely in the study (e.g. psychiatric disorder or substance abuse)
Contact & Investigator
Barry Borlaug, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06220396 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06220396 currently recruiting?
Yes, NCT06220396 is actively recruiting participants. Contact the research team at ploof.alyssa@mayo.edu for enrollment information.
Where is the NCT06220396 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06220396 clinical trial?
NCT06220396 is sponsored by Mayo Clinic. The principal investigator is Barry Borlaug, MD at Mayo Clinic. The trial plans to enroll 80 participants.